VIGL

Vigil Neuroscience, Inc.

3.14 USD

Last updated Nov 29, 07:41 UTC

Yesterday HIGH

$3.4

Yesterday LOW

$2.98

52w HIGH

$13.55

52w LOW

$2.85

EPS

-0.53

PE

-5.92

Next Earnings

Mar 19, 2024

Overview News Insider Transactions Government Trades

Vigil Neuroscience, Inc. stock is down -60.45% since 30 days ago. The next earnings date is Mar 19, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 1 November’s closed higher than October. 100% of analysts rate it a buy.

Vigil Neuroscience, Inc. engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) The company also develops a small molecule TREM2 agonist suitable for oral delivery.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

Benzinga Newsdesk

Fri Sep 8, 2023

Vigil Neuroscience Inc Says Phase 1 Dosing Expected To Commence In October 2023; No Anticipated Delays In Current Clinical Development Plans; IND For VG-3927 Now Open

-
Benzinga Newsdesk

Fri Sep 8, 2023

Vigil Neuroscience Announces Update On Its Small Molecule TREM2 Agonist Program; Company Expects To Receive Additional Details From FDA Within Next 30 Days; Will Work Closely With FDA To Address Partial Clinical Hold

- Announced VG-3927 as lead candidate to enter clinical development for potential treatment of Alzheimer's Disease -- IND for VG-3927 now open; Phase 1 clinical trial in healthy volunteers allowed to proceed with partial
Benzinga Insights

Thu Sep 7, 2023

Stocks That Hit 52-Week Lows On Thursday

On Thursday, 283 companies set new 52-week lows.
Benzinga Insights

Wed Aug 9, 2023

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 155 companies set new 52-week lows.
richadhand@benzinga.com

Wed Aug 9, 2023

HC Wainwright & Co. Reiterates Buy on Vigil Neuroscience, Maintains $24 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Vigil Neuroscience (NASDAQ:VIGL) with a Buy and maintains $24 price target.
Benzinga Insights

Tue Aug 8, 2023

Stocks That Hit 52-Week Lows On Tuesday

During Tuesday's trading, 188 companies set new 52-week lows.
Benzinga Newsdesk

Tue Aug 8, 2023

Vigil Neuroscience Q2 EPS $(0.52) Up From $(0.60) YoY

Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.52) per share. This is a 13.33 percent increase over losses of $(0.60) per share from the same period last year.
Benzinga Insights

Wed May 10, 2023

Vigil Neuroscience: Q1 Earnings Insights
Benzinga Newsdesk

Wed May 10, 2023

Vigil Neuroscience Q1 EPS $(0.51) Beats $(0.53) Estimate; Cash Balance Of $164.5M Expected To Fund Its Operational Plans Into Q1 Of 2025

Vigil Neuroscience (NASDAQ:VIGL) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.53) by 3.77 percent. This is a 12.07 percent increase over losses of $(0.58) per share from
Benzinga Newsdesk

Mon May 8, 2023

Vigil Neuroscience Launches ALSPAware Program To Provide No-cost Genetic Testing And Counseling For Adult-Onset Leukoencephalopathy With Axonal Spheroids And Pigmented Glia

Wedbush

Fri Nov 17, 09:06

buy

confirm
Wedbush

Wed Nov 8, 08:58

buy

confirm

Advanced Data Unlock

Magovcevic Ivana, Director

Mon Nov 20, 2023

VIGL Recent Insider Trades and Stock Chart

4,000 shares bought

Advanced Data Unlock

TSLA $248.31 USD

AZEK $31.54 USD

BABA $76.74 USD

YANG $11.42 USD

SPOT $182.60 USD

CRWD $209.99 USD